Major Industry Shake-Up! A Leading Player Expands Its Footprint with Two New Acquisitions – What’s the Big Plan?

These elections not only test the waters of political fortitude but also serve as a bellwether for investor confidence and economic strategies moving forward.

The stock is up by 60 per cent from its 52-week low and gave multibagger returns of 130 per cent in the last 3 years.

The share of the company gained over 40 per cent in the last six months.

The stock has gained more than 20 per cent in the last 6 months.

The company's total sales for the month stood at 82,954 units, a significant increase from the 78,335 units recorded in October 2022. This impressive growth can be primarily attributed to the stellar performance in both the Commercial Vehicle (CV) and Passenger Vehicle (PV) segments.

The shares of the company have an ROE of 32 per cent and an ROCE of 40.7 per cent. Investors should keep an eye on this IT stock under the radar.

Shares of this company have gained more than 50 per cent in the last one year.

The company has attracted significant buying interest due to its outstanding returns of over 9 per cent.

The company has a ROCE of 61.2 per cent and a ROE of 54.4 per cent. Moreover, the company has a dividend payout ratio of 24 per cent.

Large-cap stocks represent well-established companies with a market cap of Rs 20,000 crore or higher. Market cap is determined by multiplying the share price by the total number of outstanding shares, providing an estimation of a company's overall value.

The remaining 40 per cent of the equity share capital would be bought over the fiscal year 2025-2026 for a maximum consideration of Rs 360 crore

The company has delivered returns of 23 per cent over the 1 past year and returns of 48 per cent over the past 3 years. Additionally, the company has a ROE of 13.7 per cent. 

A global pharmaceutical company, has announced the launch of Thiamine Hydrochloride Injection USP, following the approval of its alliance partner Caplin Steriles Limited's ANDA by the U.S. FDA.

The stock has risen over 35 per cent in the last one year.

Over the past 3 years, the company generated returns of 50 per cent, while over the last 5 years, it achieved remarkable returns of 145 per cent.

Over the past 3 years, the company generated returns of 50 per cent, while over the last 5 years, it achieved remarkable returns of 145 per cent. Moreover, the company experienced a sales growth of 11 per cent (CAGR) and a profit growth of 48 per cent (CAGR) during the same 5-year period. 

The company has delivered stellar returns of 164.3 per cent in the last 3 years. Additionally, it maintains a ROCE of 23.8 per cent and a ROE of 20.4 per cent. Moreover, the company has a dividend yield of 36.5 per cent.

Shares of this company jumped more than 25 per cent in the last 6 months.     

The acquisition enhances their ability to address client needs and add significant value to their UK business by bringing in marquee client relationships and innovative service delivery and customer engagement models through Microsoft’s Business Applications. 

The stock has risen over 35 per cent in the last one year.   

In the broader market, BSE Mid-cap Index is up by 0.47 per cent and BSE Small-cap Index is up by 0.49 per cent.

Dividend-paying companies are always valued in the stock market as they share profits with their shareholders.

The stock is up by 14.43 per cent in 6 months and gave multibagger returns of 165 per cent in the last 2 years.

The Nifty auto sector has rallied 40 per cent from March 2022 lows and this stock is consolidating by forming lower highs and equal lows in the range of Rs 536 on higher side and Rs 366 on lower side.